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OBJECTIVES The purpose of this study was to assess the relative proportions of normal versus impaired left
ventricular (LV) systolic function among persons with congestive heart failure (CHF) in the
community and to compare their long-term mortality during follow-up.
BACKGROUND Several hospital-based investigations have reported that a high proportion of subjects with
CHF have normal LV systolic function. The prevalence and prognosis of CHF with normal
LV systolic function in the community are not known.
METHODS We evaluated the echocardiograms of 73 Framingham Heart Study subjects with CHF (33
women, 40 men, mean age 73 years) and 146 age- and gender-matched control subjects
(nested case–control study). Impaired LV systolic function was defined as an LV ejection
fraction (LVEF) ,0.50.
RESULTS Thirty-seven CHF cases (51%) had a normal LVEF; 36 (49%) had a reduced LVEF. Women
predominated in the former group (65%), whereas men constituted 75% of the latter group.
During a median follow-up of 6.2 years, CHF cases with normal LVEF experienced an
annual mortality of 8.7% versus 3.0% for matched control subjects (adjusted hazards ratio 5
4.06, 95% confidence interval 1.61 to 10.26). Congestive heart failure cases with reduced
LVEF had an annual mortality of 18.9% versus 4.1% for matched control subjects (adjusted
hazards ratio 5 4.31, 95% confidence interval 1.98 to 9.36).
CONCLUSIONS Normal LV systolic function is often found in persons with CHF in the community and is
more common in women than in men. Although CHF cases with normal LVEF have a lower
mortality risk than cases with reduced LVEF, they have a fourfold mortality risk compared
with control subjects who are free of CHF. (J Am Coll Cardiol 1999;33:1948–55) © 1999
by the American College of Cardiology
Congestive heart failure (CHF) is a major public health
problem that is associated with markedly diminished sur-
vival (1,2). Several studies have reported that a high pro-
portion of patients with CHF have normal left ventricular
systolic function (3–6), and they described a better progno-
sis for these subjects (7–9) compared with those who have
CHF with impaired left ventricular systolic function. These
previous reports were hospital-based, used heterogeneous
criteria for defining heart failure and reported widely varying
prevalence and mortality rates (3–10). The reported propor-
tion of CHF patients with normal left ventricular systolic
function has ranged from 13% to 75%, and the reported
annual mortality rate has varied from 1.3% to 17.5% (10).
The prevalence and prognosis of CHF with normal left
ventricular systolic function in the community are not
known.
The objectives of this investigation were to assess the
relative proportions of normal versus impaired left ventric-
ular systolic function among persons with CHF in a
community-based study sample and to examine their long-
term mortality.
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METHODS
Study sample. The Framingham Heart Study began in
1948 with the enrollment of 5,209 men and women
between the ages of 28 and 62 years. In 1971, children of the
original study population and the spouses of those children
(totaling 5,124) were enrolled in the Framingham Offspring
Study. The selection criteria and design of these studies
have been described previously (11,12). Participants in these
studies were examined at intervals of 2 (original study) or 4
(Offspring Study) years to assess the occurrence of cardio-
vascular disease. Each examination included a medical
history, physical examination, blood pressure measure-
ments, 12-lead electrocardiogram and laboratory tests. Rou-
tine two-dimensional echocardiography was performed on
study participants starting at the 18th biennial examination
of the original cohort and the 3rd Offspring Study exami-
nation.
Original Framingham Heart Study subjects who attended
the 18th, 19th or 20th biennial examinations (1983 to 1990)
and Offspring Study participants who attended the 3rd or
4th examinations (1984 to 1991) constituted the study
sample. A total of 123 subjects with CHF were alive at the
time of these examinations. A diagnosis of CHF was
established by the simultaneous presence of at least two
major criteria, or one major plus two minor criteria (13). Of
the 123 subjects with CHF, 50 subjects (40%; 22 men and
28 women) were excluded: 15 (12%; 7 men and 8 women)
because they did not attend any examination during the
study period, 33 (27%) because of unavailable (n 5 25; 9
men and 16 women) or inadequate (n 5 8; 4 men and 4
women) echocardiograms and 2 others (both men) because
the episode of CHF antedated the index examination by
more than 15 years. Seventy-three (60%) CHF cases had an
available and adequate echocardiogram after the onset of
CHF and were eligible for the present investigation.
Study design and definition of covariates. The study was
designed as a nested case–control study with a prospective
follow-up component. Each of the 73 CHF cases was
matched with two control subjects who were of the same age
and gender, were free of CHF and had an available and
adequate echocardiogram at that examination. These 146
control subjects constituted a comparison group for the
CHF subjects for evaluating prognosis. For the purpose of
the present study, hypertension was defined as a systolic
blood pressure $140 mm Hg or a diastolic blood pressure
$90 mm Hg or the use of antihypertensive drugs (14).
Blood pressure measures used for ascertainment of hyper-
tension status were readings obtained at the examination
immediately before CHF onset. All other covariates were
ascertained at the index examination. Criteria for diabetes
mellitus, electrocardiographic left ventricular hypertrophy,
atrial fibrillation and coronary disease have been described
previously (15).
Echocardiographic methods. At the index examinations,
all participants routinely underwent M-mode, and two-
dimensional echocardiography. All echocardiograms of the
eligible participants (73 CHF cases and 146 control sub-
jects) were analyzed by an experienced observer with a
randomized sequencing of studies. The observer was
blinded to all clinical information regarding the study
subjects. For the CHF cases, the first echocardiogram
obtained after the date of onset of CHF was selected if
multiple echocardiographic studies were available. The ob-
server visually estimated the left ventricular ejection fraction
(LVEF) to the nearest 2.5% based on assessment of left
ventricular contractile function in multiple echocardio-
graphic views (16). The accuracy and reproducibility of such
a visual estimate of ejection fraction has been established in
several reports (17–20). For the purposes of this study, CHF
subjects were divided into two groups: those with normal
left ventricular systolic function (LVEF $0.50) and those
with impaired left ventricular systolic function (LVEF
,0.50); for convenience, these two groups are referred to as
“normal-systolic” and “systolic” CHF, respectively. Such a
division of the CHF cases resulted in the splitting of the
control subjects into two groups. Thus, for systolic CHF
cases and for normal-systolic CHF cases we had separate
age- and gender-matched comparison groups.
Follow-up. All study subjects were routinely followed for
up to 10 years. The primary end point was death due to any
cause. The duration of follow-up was defined as the interval
from the date of the index examination at which the
echocardiogram was obtained to the date of death or the
date of last contact. All deaths were reviewed by a panel of
three experienced investigators who determined the cause of
death by evaluating all pertinent available medical records
and by communication with personal physicians and family
members. Cardiovascular disease events included coronary
heart disease (angina pectoris, coronary insufficiency, myo-
cardial infarction and sudden or nonsudden death attribut-
able to coronary heart disease), congestive heart failure,
cerebrovascular disease and peripheral vascular disease. Cri-
teria for cardiovascular and noncardiovascular disease events
have been detailed previously (21).
Statistical methods. The proportions of CHF patients
with normal versus reduced LVEF were determined from
frequency tables, and their 95% confidence intervals (CIs)
were calculated. Among the CHF cases, logistic regression
analysis (22) was used to examine if select factors were
associated with the presence of normal versus reduced
LVEF. Survival curves for the two CHF groups and their
Abbreviations and Acronyms
CHF 5 congestive heart failure
CI 5 confidence interval
LVEF 5 left ventricular ejection fraction
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age- and gender-matched control subjects were estimated
using the Kaplan-Meier product-limit estimator and they
were compared using the log-rank test (23). Survival of
CHF cases was compared with that of the matched control
subjects using Cox proportional hazards regression for
matched sets. Among the CHF cases, the influence of
normal versus reduced LVEF on survival was examined
using Cox proportional hazards regression models. Multi-
variable models were generated adjusting for covariates with
a p value ,0.20. The covariates eligible for entry in the final
models included gender, age, history of coronary heart
disease, history of stroke, atrial fibrillation, left ventricular
hypertrophy on the electrocardiogram, diabetes, pulmonary
disease, cigarette smoking, valvular disease and systolic and
diastolic blood pressure. Duration of CHF was included as
a covariate for analyses comparing survival in the two CHF
subgroups. A p value ,0.05 was considered statistically
significant. All analyses were performed utilizing the SAS
System (SAS Institute, Cary, North Carolina) procedures
LOGISTIC, LIFETEST and PHREG (24).
RESULTS
Prevalence of normal left ventricular ejection fraction
among CHF cases. The study sample consisted of 73
CHF cases (40 men, 33 women, mean age 73 years) and 146
age- and gender-matched control subjects (80 men and 66
women). The median duration of CHF at the time of
echocardiographic assessment was 2.8 years (range 0.1 to 15
years) and was similar for men and women. Thirty-seven
CHF cases (51%, 95% CI 40% to 62%) had normal LVEF,
whereas 36 CHF cases (49%, 95% CI 38% to 60%) had
reduced LVEF. Of 33 women with CHF in the study
sample, only nine (27%; 95% CI 11% to 43%) had reduced
LVEF. In contrast, of 40 men with CHF, 27 (67.5%; 95%
CI 52% to 82%) had reduced LVEF. The distribution of
values of LVEF among CHF cases is depicted in Figure 1.
Among control subjects, 136 out of 146 had normal LVEF;
of the 10 control subjects with reduced LVEF, eight had a
history of prior myocardial infarction.
Clinical features of systolic and normal-systolic CHF.
The baseline clinical characteristics of the CHF cases (with
normal and reduced LVEF) and their matched control
subjects are shown in Table 1. Coronary disease, atrial
fibrillation, diabetes, valve disease and electrocardiographic
left ventricular hypertrophy were more common in CHF
cases than in control subjects. The two CHF groups did not
differ with regard to the duration of CHF, smoking habits
or alcohol consumption. It is noteworthy that over 40% of
normal-systolic CHF cases were taking digoxin without a
history of atrial fibrillation.
Among the CHF cases, multiple logistic regression analyses
revealed an association of female gender with the presence of a
normal LVEF (odds ratio for reduced LVEF 0.25, 95% CI
0.08 to 0.77). Prior myocardial infarction was associated with
an increased likelihood of having CHF with reduced LVEF
(odds ratio 4.6, 95% CI 1.5 to 13.9). Diabetes mellitus, atrial
fibrillation and hypertension were not associated with presence
or absence of reduced LVEF among CHF cases.
Survival of CHF cases and control subjects. Heart failure
cases and matched control subjects were followed for a
median duration of 6.2 years (range 0.1 to 10.4 years) after
the examination at which the echocardiogram was obtained.
The 219 study subjects contributed 1,323 person years of
observation. No subject was lost during follow-up, during
which time there were 79 deaths. Seventeen of 37 normal-
systolic CHF cases (46%) died, compared with 15 of the 74
matched control subjects (20%). Twenty-seven of 36 sys-
tolic CHF cases (75%) died, compared with 20 of 72
matched control subjects (28%).
Heart failure cases with reduced LVEF had an annual
mortality of 18.9%, compared with an annual mortality of
4.1% in age- and gender-matched control subjects. Heart
failure cases with normal LVEF experienced an annual
mortality of 8.7%, compared with a mortality rate of 3.0% in
matched control subjects. Figures 2 (panels A and B) and 3
(panels A and B) depict the Kaplan-Meier survival plots for
the two CHF groups and their respective control subjects.
In men and women survival was worse among those with
CHF than in age-matched control subjects; this applied to
both CHF groups. Survival plots for subjects with normal-
systolic CHF compared with those with systolic CHF are
presented in Figure 4. The median survival of the normal-
systolic CHF group was 7.1 years, compared with a median
survival of 4.3 years for the systolic CHF group.
Survival of each CHF group was also compared with that
of its control group using analyses for matched sets. Com-
pared with age- and gender-matched control subjects, and
adjusting for covariates (Table 2), both normal systolic
CHF and systolic CHF were associated with a fourfold
Figure 1. The distribution of left ventricular ejection fraction
(LVEF) values among men and women with congestive heart
failure is displayed in the figure. Twenty-seven of 40 men (67.5%)
had a reduced LVEF (,0.50), compared with only nine of 33
women (27%).
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mortality risk (for normal systolic CHF, hazards ratio 5
4.06, 95% CI 1.61 to 10.26; for systolic CHF, hazards
ratio 5 4.31, 95% CI 1.98 to 9.36).
To evaluate the impact of reduced left ventricular ejection
fraction on the survival of CHF cases, several statistical
models were explored. In proportional hazards models
adjusted only for age, a 51% lower hazard for death was
observed in normal-systolic CHF cases compared with
systolic CHF cases (Table 3). In view of the striking gender
differences in the composition of the two CHF groups and
the reported favorable influence of female gender on survival
of CHF cases (2,25,26), regression models incorporating
gender were studied. In models adjusting for other covari-
ates, female gender was associated with a 61% lower hazard
for death; the association of normal-systolic CHF with a
lower mortality was no longer statistically significant once
gender was incorporated. These results were not affected
when we stratified according to the presence or absence of
valve disease, or when the variable left ventricular mass/
height was forced into the multivariable models. When the
effect of LVEF on the mortality risk of CHF cases was
examined in multivariable models using LVEF as a contin-
uous variable, a 5% increment in LVEF was associated with
a 13% lower hazard of death (hazards ratio 5 0.87, 95% CI
0.77 to 0.99; p 5 0.039).
To obtain insights into the bias inherent in selecting
subjects with adequate echocardiograms, we compared sur-
vival of the 73 CHF cases included in the study sample with
that of the 33 CHF cases who were excluded because of
unavailable or inadequate echocardiograms. Survival was
significantly better for CHF cases included in the present
investigation (hazard ratio for death 5 0.54, p , 0.023)
compared with the excluded CHF cases, reflecting the lower
mortality risk of our study sample.
The cause of death could be ascertained in 75 of the 79
subjects who died on follow-up. Forty-seven percent of deaths
among CHF patients with a normal LVEF, and 60% of deaths
among CHF patients with a reduced LVEF were attributed to
cardiovascular events. In comparison, cardiovascular diseases
accounted for only 36% of deaths among the control subjects.
DISCUSSION
Although the epidemiology of CHF has been well charac-
terized (1,2,27,28), the relative contributions of impaired
versus intact LV systolic function to the prevalence of this
Table 1. Clinical Characteristics of Congestive Heart Failure Cases and Control Subjects*
Variable
CHF with
Reduced LVEF
(n 5 36)
Controls for
CHF with
Reduced LVEF
(n 5 72)
CHF with
Normal LVEF
(n 5 37)
Controls for
CHF with
Normal LVEF
(n 5 74)
Age (yr) 74 6 7 74 6 7 72 6 9 72 6 9
Male (%) 75 75 35 35
Coronary disease (%) 72 17 57 15
Myocardial infarction (%) 69 7 24 7
Angina pectoris (%) 36 13 46 14
Diabetes mellitus (%) 22 6 14 3
Atrial fibrillation (%) 36 6 35 5
Smoker (%)† 14 15 14 11
Alcohol intake (oz/week) 2.8 6 4.6 2.9 6 3.6 2.2 6 4.1 2.1 6 3.4
Valve disease (%)‡ 25 6 19 8
Systolic BP (mm Hg) 138 6 21 144 6 19 143 6 24 142 6 24
Diastolic BP (mm Hg) 75 6 10 77 6 11 73 6 13 76 6 10
Hypertension (%) 71 54 75 62
ECG LVH (%) 14 4 22 3
Median CHF duration (yr) 3.2 — 2.3 —
Drug treatment (%)
Beta blockers 11 22 32 21
Diuretics 67 33 68 38
ACE inhibitors 36 2 19 5
Calcium channel blockers 14 1 14 8
Digoxin
With atrial fibrillation 25 2 29 2
Without atrial fibrillation 32 10 42 7
Nitrates 39 6 46 7
*All variables (other than hypertension status) for CHF cases and control subjects are defined at the time of the index examination at which the echocardiogram was obtained.
Hypertension status was determined at the examination immediately preceding the onset of CHF. †Refers to smoking in the year before the index examination. ‡Refers to valve
disease defined on the echocardiogram, i.e., moderate or greater degree of valve stenosis or regurgitation.
ACE 5 angiotensin-converting enzyme; BP 5 blood pressure; CHF 5 congestive heart failure; ECG 5 electrocardiogram; LVEF 5 left ventricular ejection fraction; LVH 5
left ventricular hypertrophy.
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disease and their respective prognoses in the community are
not known. Prior investigations of normal-systolic heart
failure were hospital-based and suffered from several meth-
odological limitations (10). We used echocardiography to
evaluate left ventricular systolic performance in a prevalence
cohort of CHF cases to assess the proportion with reduced
and normal systolic function and to define their long-term
prognoses.
Prevalence and predictors of normal left ventricular
ejection fraction among CHF cases. We found that about
half the CHF cases in our community-based sample had
normal LVEF. Our results confirm and extend to the
community prior findings from hospital-based series (3–10),
which highlighted the frequent presence of normal left
ventricular systolic function among CHF patients. Our
findings also concur with estimates from the Helsinki
Ageing Study (29) and with a preliminary report from the
Cardiovascular Health Study (30).
In the present investigation, prior myocardial infarction
was associated with systolic CHF. This observation is
consistent with the well recognized adverse impact of
myocardial damage on left ventricular contractility. Women
with CHF were more likely than men to have a normal
LVEF; among CHF cases, three quarters of the women had
normal LVEF compared with one third of men. This
finding is consistent with prior reports of a female prepon-
derance among patients with CHF and normal left ventric-
ular systolic function (3–5,31). Female gender has also been
consistently associated with higher indexes of ventricular
systolic performance in studies of experimental animals
Figure 2. Kaplan-Meier survival plots of control and congestive
heart failure (CHF) subjects with reduced left ventricular ejection
fraction (LVEF) are displayed. Survival of men (A) and women
(B) with CHF with reduced LVEF was lower than that of
age-matched control subjects of the same gender. The overall
5-year survival for CHF cases with reduced LVEF was only 36%,
compared with 78% for matched control subjects (log-rank p ,
0.0001).
Figure 3. Kaplan-Meier survival plots of control and CHF sub-
jects with normal LVEF are displayed. Survival of men (A) and
women (B) with CHF with normal LVEF was lower than that of
age-matched control subjects of the same gender. The overall
5-year survival was 68% for CHF cases with normal LVEF,
compared with 82% for matched control subjects (log-rank p ,
0.0001). Abbreviations as in Figure 2.
Figure 4. Kaplan-Meier survival plots of CHF patients with
normal and reduced LVEF are displayed. The overall survival of
CHF subjects with reduced LVEF is worse than that of CHF
subjects who have a normal LVEF. This comparison does not
account for gender differences in the composition of the two
groups. Abbreviations as in Figure 2.
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(32,33), healthy human subjects (34), patients with valvular
aortic stenosis (35–37) and subjects with hypertension
(38,39). Similarly, a preponderance of women has also been
noted among elderly patients with hypertensive hypertropic
cardiomyopathy (40).
Mortality of subjects with CHF and normal left ventric-
ular ejection fraction. Despite the selection of a healthier
sample of CHF cases in the present investigation, mortality of
normal-systolic CHF cases was about four times that of age-
and gender-matched control subjects without CHF (multiva-
riable model results, Table 2). Nonetheless, mortality risk of
this group was only about half that of systolic CHF cases. Due
to a small sample size, we were unable to determine definitively
whether the better prognosis of normal-systolic CHF cases
(compared with systolic CHF cases) was due to a greater
proportion of women in this group or if it was related to the
preservation of left ventricular contractile function. Among
CHF patients, women, especially those with a nonischemic
etiology of heart failure, have been noted to have a better
prognosis than men (41).
The prognosis of our normal-systolic CHF cases resem-
bles that reported for CHF patients with preserved left
ventricular systolic function in the V-HEFT study (7) but is
worse than that reported in another investigation (42). It
must be pointed out that our CHF cases were considerably
older than patients in the latter report (42). In other
hospital-based investigations (43–45) the mortality of CHF
cases with a normal LVEF was higher than in our study, in
part because they included sicker individuals.
Strengths and limitations. Our study sample was a prev-
alence cohort of ambulatory subjects with chronic CHF.
Such a community-based sample more closely represents the
population of patients with chronic CHF who are followed
by physicians on an outpatient basis (46). The use of well
defined criteria for the diagnosis of CHF, the availability of
matched control subjects from the same cohort, the routine
nature of the echocardiogram and its blinded assessment,
and the regular surveillance of the study sample for the
development of morbid events are additional strengths of
the present investigation.
Nevertheless, our study has several limitations. Our study
sample consisted of prevalent cases who survived for a
median of 2.8 years after onset of CHF before receiving an
echocardiogram. Clinical correlates and mortality of such a
prevalence cohort may differ from those of an incidence
cohort of CHF cases (47). Due to the long interval between
the onset of CHF and the echocardiographic assessment of
left ventricular function, the left ventricular ejection fraction
at the time of the index examinations may not represent that
at onset of CHF; serial changes and spontaneous fluctua-
tions in left ventricular ejection fraction among CHF
subjects have been described (48,49). The exclusion of CHF
cases due to nonavailability of an echocardiogram also
Table 3. Impact of Normal Versus Reduced Left Ventricular Ejection Fraction on the Mortality
of Congestive Heart Failure Cases: Results of Cox Proportional Hazards Regression Models
Model
Hazard Ratio
for Death
95% CI
Hazard Ratio
p
Value
I. Age-adjusted models
Age 1.55 1.14–2.11 0.005
CHF with normal LVEF 0.49 0.27–0.91 0.023
II. Models with age and gender
Age 1.55 1.14–2.11 0.006
Female gender 0.65 0.33–1.28 0.21
CHF with normal LVEF 0.59 0.30–1.16 0.13
III. Covariate*-adjusted models
Age 1.57 1.10–2.25 0.013
Female gender 0.39 0.18–0.86 0.019
CHF with normal LVEF 0.65 0.31–1.35 0.25
*Covariates included diabetes, smoking status, systolic and diastolic blood pressure and duration of CHF. Hazard rates represent
values for increments of 1 standard deviation for age (8 years), for female gender and for presence of CHF with normal LVEF.
The hazard rate associated with CHF with normal LVEF changed minimally when left ventricular mass was forced into this
model (hazards ratio 5 0.66, 95% CI 0.26 to 1.69; p 5 0.39). Abbreviations as in Table 2.
Table 2. Impact of Congestive Heart Failure on Mortality:
Results of Multivariable Cox Proportional Hazards
Regression Models
Hazard Ratio
for Death
95% CI
Hazard Ratio
p
Value
CHF with reduced LVEF
vs. age- and gender-
matched controls*
4.31 1.98–9.36 0.0002
CHF with normal LVEF
vs. age- and gender-
matched controls*
4.06 1.61–10.26 0.003
*Covariates included age, gender, history of coronary disease, diabetes, atrial fibrilla-
tion, valve disease, smoking status, systolic blood pressure and pulmonary disease.
Variables not included (p $ 0.20 in stepwise models) were electrocardiographic left
ventricular hypertrophy, stroke and diastolic blood pressure. When left ventricular
mass was forced into the stepwise models, the hazard ratio for death was marginally
reduced thus: CHF with reduced LVEF: 3.74 (95% CI 1.66 to 8.44); CHF with
normal LVEF: 3.71 (95% CI 1.25 to 11.00).
CHF 5 congestive heart failure; CI 5 confidence interval; LVEF 5 left
ventricular ejection fraction.
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constitutes a drawback. The choice of ejection fraction (a
load-dependent measure) as an index of left ventricular
systolic performance also may be questioned. There is some
evidence to suggest that patients with a normal ventricular
ejection fraction but with high relative wall thickness may
have depressed myocardial contractile function when more
sensitive measures of left ventricular performance (such as
midwall fractional shortening) are used (50,51). The selec-
tion of a partition value of 50% for separating normal from
reduced LVEF may be criticized. It is uncertain, for
instance, if an LVEF value of 45%, is depressed enough to
initiate the maladaptive changes associated with the syn-
drome of CHF. We chose this partition value because it is
the most frequently utilized cut point in published reports
for separating normal left ventricular systolic function from
systolic dysfunction (10).
Our data on the prognosis of CHF patients should also
be interpreted with caution because a majority of patients in
the study had CHF onset before 1990. Several reports have
underscored the improvement in prognosis of CHF patients
with impaired left ventricular systolic function in the period
after 1990, in part related to major therapeutic advances
(52–56). Last, our study population was elderly and most
subjects were white; extrapolation of these findings to other
populations or to different age groups may be inappropriate
(57).
Clinical implications. The prevalence of CHF is esti-
mated to be from 1% to 3% of the adult population
worldwide, with a steep increase to approximately 10% in
the elderly (1,2,25,28,58,59). Our study points out that a
substantial proportion of ambulatory patients with CHF
have normal left ventricular systolic function. The current
treatment of patients with CHF who have normal left
ventricular systolic function is empirical (10). The substan-
tial burden of this condition and its unfavorable prognosis
emphasize the need for controlled clinical trials to define the
optimal treatment of these patients.
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